A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
54
GSK835726 (10mg) tablet
GSK835726 (50mg) tablet
GSK835726 (100mg) tablet
GSK Investigational Site
Hanover, Lower Saxony, Germany
Change from baseline in total nasal symptom score 0-4 hours post dose
Time frame: 0-4 hours post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cetirizine (10mg) tablet as positive control
Placebo to match active